Estimating the impact of ENESTnd trial data

A new Sermo Event Report™ surveyed 141 Hematologists/Oncologists to measure the impact of ENESTnd trial data on Oncologist’s use of Tasigna, Sprycel and Gleevec in newly diagnosed CML patients. The report also assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in a front line setting.

According to the report, Oncologists find Tasigna front line data convincing and plan to increase its use in this setting post-FDA approval. However, many are still looking for additional endpoints before making a final judgment. Interestingly, there is not much familiarity of Tasigna front line data in the physician community, even among those who attended ASH 2009.

Highlights of the report include:

• Insight into changing landscape of treatments for newly diagnosed CML patients.
• Physicians’ perception of cytogenetic and molecular measures in predicting long-term outcomes and their impact on choice of CML therapy.
• Off-label use of Sprycel and Tasigna.
• Physicians’ impression of Tasigna’s front line data versus Gleevec’s in newly diagnosed Ph+ CML patients.
• Impact of ENESTnd data in evolving treatment choices for front line patients.

Respondents Familiarity with Tasigna’s Front Line Data

While most survey respondents had some familiarity with the ENESTnd trial, there were only 14% who claimed to be well versed with the data.